Company intelligence / Profile preview

Polyphor

Ownership: Private
Development stage: Phase 3

Overview

Completed enrollment in Phase III balixafortide (FORTRESS) trial in 2020 with data readout expected in 2021. Also had multiple programs in earlier clinical stages.

Therapeutic areas: OncologyPulmonologyRare DiseasesInfectious Diseases
Modalities: Macrocyclic drugsAntibiotics
Industry: Biotech

Drug pipeline

1 asset

s-thanatin

Preclinical

Partnerships

NovartisBoehringer IngelheimCARB-X

Beyond the preview

Go deeper on Polyphor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polyphor.

Explore the full profile